Lupin receives approval for Loteprednol Etabonate Ophthalmic Suspension

0

Mumbai, Dec 28 (UNI)- Pharma major Lupin said that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2%, to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc.

The product will be manufactured at Lupin’s Pithampur facility in India. Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.

Loteprednol Etabonate Ophthalmic Suspension, 0.2%, had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).

You might also like
Leave a comment